# Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma

> **NCT07430579** · NA · RECRUITING · sponsor: **The Second Hospital of Shandong University** · enrollment: 25 (estimated)

## Conditions studied

- Pathological Complete Remission
- Objective Response Rate
- Immune-related Adverse Events
- Quality of Life

## Interventions

- **PROCEDURE:** adebrelimab combined with chemotherapy

## Key facts

- **NCT ID:** NCT07430579
- **Lead sponsor:** The Second Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07430579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07430579, "Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07430579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*